Kimford Meador, MD, FAAN, Stanford University, Stanford, CA, outlines findings from the MONEAD study (NCT01730170), which aimed to assess developmental outcomes in newborns breastfeeding from mothers with epilepsy receiving antiseizure medications. The cohort included mothers being treated with a variety of medications including lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, and combination therapies. No adverse effects were reported in the infants, which corroborated with previous studies and the higher metabolism in neonates may contribute to the reduced levels of the medications in the bloodstream. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Research support from the National Institutes of Health and Eisai Inc; the Epilepsy Study Consortium pays Dr. Meador’s university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma, and Vivus Pharmaceuticals.